Harvard geneticist David Sinclair proposes that aging is caused by loss of epigenetic information, not just genetic damage.
David Sinclair stands as one of the most influential and controversial figures in modern longevity research. As a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research, Sinclair has spent the last two decades pursuing a singular obsession: understanding the fundamental nature of aging itself. His journey to this position was not inevitable. After earning his PhD at the University of New South Wales in his native Australia, Sinclair spent his early career studying yeast, a humble organism that would reveal surprising truths about aging applicable across the entire tree of life. This foundation in basic science, combined with an unusual willingness to make bold theoretical claims about mechanisms most scientists treated as immutable facts of nature, would ultimately position him as both a champion of aging research and a lightning rod for criticism.
Sinclair's popular book "Lifespan: Why We Age—and Why We Don't Have To" became a New York Times bestseller, introducing millions of readers to the idea that aging is not an uncontrollable force of nature but a disease that could potentially be prevented, treated, or even reversed. This claim, which would seem almost heretical in traditional medical circles, has become increasingly mainstream, partly due to Sinclair's tireless efforts to communicate his research to both scientific and general audiences. Yet behind the compelling narratives and media appearances lies a substantial body of scientific work that attempts to answer one of humanity's oldest questions: What is aging, fundamentally, and can we do something about it?
The traditional view of aging, which dominated gerontology for most of the twentieth century, was essentially a passive process of accumulated damage. DNA accumulates mutations from radiation, oxidative stress, and replication errors. Proteins misfold. Cellular machinery degrades. The body eventually reaches a point where it simply cannot maintain itself, and death becomes inevitable. This damage accumulation model has substantial evidence supporting it, and no serious biologist would claim it plays no role in aging. But Sinclair has proposed something different, a theory that has come to be known as the Information Theory of Aging. Rather than focusing on physical damage to DNA as the primary driver of aging, Sinclair proposes that aging is fundamentally caused by loss of epigenetic information—the instructions that tell your cells how to read and interpret your DNA.
The distinction might seem subtle, but it is profound. Imagine DNA as a compact disc, perfectly intact and containing all your genetic information. The CD itself is not scratched or damaged, but the CD player—the machine that reads the information on the disc—has degraded over time. The data on the disc is still perfect, but you can no longer read it correctly. The cell no longer knows what genes to turn on and off at the right times in the right amounts. This is the essence of Sinclair's theory. Aging is not primarily about broken genes, but about the breakdown of the epigenetic regulatory system that determines which genes are expressed and when. As we age, this epigenetic information becomes increasingly corrupted, and cells lose their ability to maintain their proper identity and function.
This theory is not merely abstract speculation but is grounded in Sinclair's research on sirtuins, a family of proteins that emerged as central to understanding aging through an unexpected path. The story begins with a substance called resveratrol, a compound found in red wine, particularly in grape skins. In the 1990s, research suggested that resveratrol might have health benefits, and researchers became interested in understanding why. Sinclair's lab discovered that resveratrol activates a protein called SIRT1, one of seven sirtuins in the human body. These sirtuins are enzymes that modify proteins through a process called deacetylation, and they are fundamentally involved in cellular stress response and metabolic regulation. What made this discovery exciting was that sirtuins appeared to be involved in extending lifespan in simple organisms when their activity was increased.
The problem, however, is that sirtuins cannot function without NAD+, a coenzyme present in all living cells that serves as an essential fuel for numerous biochemical reactions. NAD+ is particularly important as a substrate for sirtuin activation, and here is where aging reveals a critical vulnerability: NAD+ levels decline dramatically as we age. By the time a person reaches age 50, their NAD+ levels are approximately half what they were at age 20. By age 80, they may be only 10 percent of youthful levels. This decline has profound consequences. As NAD+ drops, sirtuins cannot function optimally, and the cellular machinery that depends on sirtuin activity begins to falter. DNA repair mechanisms slow. Mitochondrial function deteriorates. The cell's ability to respond to stress diminishes. In this framework, boosting NAD+ levels becomes a logical intervention to restore sirtuin function and potentially restore some aspects of youthful cellular function.
This is where NMN, or nicotinamide mononucleotide, enters the picture. NMN is a precursor to NAD+, meaning the body can convert NMN into NAD+. In animal studies, NMN supplementation has shown remarkable effects. Mice given NMN show improved exercise capacity, better metabolic health, improved glucose control, and in some studies, extended lifespan. Sinclair himself has become publicly associated with NMN supplementation, and the compound has become increasingly popular among longevity-focused individuals. Yet here is where careful distinction becomes important: the evidence that NMN works in mice is substantial. The evidence that NMN works in humans to extend lifespan is nonexistent. Human studies of NMN are limited, and while some show improvements in muscular function and metabolic markers, we do not have evidence that NMN actually extends human life. This gap between animal evidence and human evidence is precisely where Sinclair's claims become most controversial.
Resveratrol occupies a similar position in Sinclair's research narrative. As mentioned, resveratrol activates SIRT1, and in animal models, resveratrol has shown benefits for metabolic health and lifespan. Sinclair himself takes resveratrol daily, always with a fat source to enhance absorption. The rationale is sound—if SIRT1 activation is beneficial, and resveratrol activates SIRT1, then taking resveratrol might extend healthspan and lifespan. Yet, like NMN, the human evidence is far more ambiguous than the animal evidence. Some human studies show benefits for metabolic markers, but we do not have evidence that resveratrol, taken as a supplement by healthy humans, extends life. This distinction between mechanistic plausibility and demonstrated efficacy is crucial for evaluating Sinclair's claims objectively.
Beyond NAD+ and sirtuins, Sinclair's recent research has focused on cellular reprogramming, an area that has generated both excitement and skepticism. The discovery of Yamanaka factors—transcription factors that can reprogram adult cells back into a pluripotent state—won Shinya Yamanaka the Nobel Prize in 2012. Sinclair's group has begun experimenting with partial cellular reprogramming, using modified versions of these factors not to fully reprogram cells but to partially reset them, theoretically restoring some youthful gene expression patterns while maintaining cell identity. Early results in mice show that this approach can reverse some markers of aging, including improvements in vision and other tissue functions. These studies are genuinely fascinating and represent cutting-edge research. However, they are also preliminary. The leap from partial reprogramming reversing some aging markers in mice to being able to do the same thing safely and effectively in humans is enormous, and claiming that such therapies are imminent would be premature.
Sinclair's personal protocol, as described in his public communications, provides a window into his beliefs about what should be done now with our current knowledge. According to interviews and his book, Sinclair takes NMN daily, typically 500 mg to 1 gram. He takes resveratrol with the NMN to optimize SIRT1 activation, understanding that the combination is more effective than either compound alone. He has discussed taking metformin, the diabetes drug now being studied in the TAME (Targeting Aging with Metformin) trial as a potential anti-aging agent. This suggests confidence that drugs normally used for disease treatment might have age-slowing properties. Beyond supplements, Sinclair practices intermittent fasting, having an eating window of roughly eight hours and fasting for sixteen. This eating pattern is believed to activate AMPK and other stress-response pathways that promote cellular repair. He exercises regularly, understanding that physical activity is one of the most robust interventions for extending healthspan. He avoids excessive sun exposure, as ultraviolet radiation damages DNA and accelerates aging. He avoids smoking and processed foods. Taken together, Sinclair's protocol combines mechanistic interventions targeting specific aging pathways with more general health maintenance behaviors.
The criticisms leveled at Sinclair and his work are worth understanding in detail because they illuminate important limitations in aging research. First, there is the matter of evidence levels. The vast majority of Sinclair's most celebrated work is in simple organisms or animal models, not in humans. For sirtuin research, most evidence comes from yeast and mice. For NMN and resveratrol, animal studies are abundant while human longevity studies do not exist. This is not necessarily disqualifying—animal research is essential for identifying promising mechanisms—but it is important context. A compound that extends lifespan in mice by 20 percent might not extend human lifespan at all, or it might extend it by 2 percent, or it might extend it only under conditions not easily replicated in humans. The translation from animal models to human benefits is notoriously difficult in aging research.
Second, there are financial entanglements that deserve scrutiny. Sinclair has founded and been involved with multiple companies developing NAD+ precursor products and other longevity interventions. While this does not prove that his scientific claims are motivated by profit—many of the most accomplished scientists have founded companies around their research—it does create the appearance of conflict of interest. A skeptical observer might wonder whether Sinclair's enthusiasm for NAD+ precursor supplementation is appropriately calibrated given the evidence, or whether the financial incentives to promote these products have influenced his public communications. Sinclair and his defenders would argue that his commitment to these therapies predates the companies and is grounded in genuine scientific belief. Others have noted that extensive media promotion of unproven supplements to treat aging, even by credible scientists, may mislead people into neglecting proven interventions like exercise and sleep.
Third, there is the question of mechanistic complexity. The idea that aging can be understood primarily as loss of epigenetic information is appealing in its elegance, but aging is likely far more complicated than any single theory proposes. Protein aggregation, mitochondrial dysfunction, cellular senescence, genomic instability, telomere shortening, immune dysfunction—these are not speculative mechanisms but documented hallmarks of aging. Some of these hallmarks may be downstream consequences of epigenetic information loss, as Sinclair proposes, but others may be partially independent processes. A complete understanding of aging will likely require integrating multiple theories rather than crown one single mechanism as the primary cause.
Fourth, there is the risk that attractive theories can distort research priorities. If aging is primarily about epigenetic information loss, then reversing epigenetic aging should be the priority. But if aging has multiple independent mechanisms, focusing disproportionately on epigenetics might cause other important research directions to be neglected. The history of science is littered with examples of compelling theories that turned out to be incomplete or partially wrong, causing entire research communities to pursue dead ends. This risk is real, though it would be unfair to suggest that Sinclair alone bears responsibility for research prioritization in the aging field.
Despite these criticisms and caveats, Sinclair's impact on the field has been undeniably significant. He has done more than perhaps anyone else to bring aging research from the margins into mainstream conversation. His book "Lifespan" introduced millions to the concept that aging is a disease that might be treatable. His research on sirtuins and NAD+ has opened genuine research directions that other labs have pursued independently, leading to substantial bodies of work. The TAME trial, testing metformin as an anti-aging intervention, would not likely have been funded without the atmosphere of possibility that Sinclair and others have created around aging research. His willingness to make bold claims, even as a Harvard professor, has helped shift the Overton window in discussions about aging, making it more acceptable to think about extending human lifespan and healthspan.
The reasonable conclusion is that Sinclair's theories are interesting and his research directions are worth pursuing, but his public claims about what people should do now, based on current evidence, often outpace the actual evidence. NMN and resveratrol might eventually prove to be valuable interventions for longevity, but that day has not yet come. His cellular reprogramming research is genuinely exciting but remains preliminary. His core theoretical insight about epigenetic aging is compelling and has merit, but it is one lens among many for understanding aging, not the definitive explanation. For individuals trying to decide what to do about aging, Sinclair's work suggests that interventions targeting specific molecular pathways might eventually be possible, but in the meantime, the proven interventions—exercise, sleep, proper nutrition, stress management, and social connection—should remain the foundation. NMN and resveratrol are not proven enough to be worth prioritizing over these fundamentals, even if they are safe enough to experiment with. Sinclair's true contribution may not be any specific compound or protocol, but rather his success in convincing the scientific community and the public that aging is worth studying seriously, that aging might not be inevitable, and that the effort to extend human healthspan and lifespan is among the noblest of scientific pursuits.